Scarica l'app Stockscreener
10.26
9.38%
0.88
Dopo l'orario di chiusura:
10.00
-0.26
-2.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
CFO Makes Bold Move with Major Stock Purchase in MoonLake Immunotherapeutics - TipRanks
MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & - GlobeNewswire
Insider Stock Purchases: October 09, 2025 - Quiver Quantitative
MoonLake Immunotherapeutics Stock (MLTX) Opinions on Phase 3 Trial Setback - Quiver Quantitative
Insider Buying: Matthias Bodenstedt Acquires Shares of MoonLake Immunotherapeutics - GuruFocus
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock - Investing.com
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock By Investing.com - Investing.com UK
BFA Law is Investigating MoonLake Immunotherapeutics (MLTX) for Securities Fraud and Urges Shareholders to Contact the Firm - Newsfile
Measuring MoonLake Immunotherapeutics’s beta against major indicesFed Meeting & Daily Growth Stock Tips - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake ImmunotherapeuticsMLTX - PR Newswire
MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with - GlobeNewswire
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
MLTX ALERT: Levi & Korsinsky Investigates MoonLake Immunotherapeutics on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Oppenheimer lowers Moonlake Immunotherapeutics stock price target after mixed trial results - Investing.com
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $25 - 富途牛牛
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics - GlobeNewswire
MoonLake Immunotherapeutics Investors Should Contact Block - GlobeNewswire
MLTX Investor News: If You Have Suffered Losses in MoonLake - GlobeNewswire
MLTX ACTIVE INVESTIGATION: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky Now - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud by MoonLake Immunotherapeutics (MLTX) - ACCESS Newswire
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm - The Malaysian Reserve
MoonLake Immunotherapeutics Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsMLTX - MarketScreener
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny - GlobeNewswire
What is HC Wainwright’s Forecast for MLTX FY2025 Earnings? - Defense World
MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm’s Investigation - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Investors to Reach Out - ACCESS Newswire
MoonLake Immunotherapeutics (MLTX): Valuation in Focus After VELA HS Trial Setback and Market Scrutiny - simplywall.st
Top 3 Health Care Stocks That Are Preparing To Pump In Q4 - Benzinga
Leading vs lagging indicators on MoonLake Immunotherapeutics performance2025 Fundamental Recap & Technical Buy Zone Confirmation - newser.com
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on - The National Law Review
Ongoing MoonLake Immunotherapeutics (MLTX) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Combining price and volume data for MoonLake ImmunotherapeuticsRisk Management & Daily Profit Focused Screening - newser.com
What earnings revisions data tells us about MoonLake ImmunotherapeuticsSwing Trade & AI Driven Stock Price Forecasts - newser.com
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
MoonLake Immunotherapeutics results for Phase 3 VELA-1, VELA-2 trials - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Stockholders to Reach Out - ACCESS Newswire
ATTENTION MLTX Shareholders: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Did MoonLake Immunotherapeutics (MLTX) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
The week in pharma: action, reaction and insight – week to October 3 - The Pharma Letter
Is MoonLake Immunotherapeutics stock a buy before product launchesJuly 2025 Opening Moves & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-05 03:26:36 - newser.com
MoonLake Immunotherapeutics Reports Positive Phase 3 Trial Results - MSN
MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces - GlobeNewswire
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $16 - 富途牛牛
MoonLake Immunotherapeutics (MLTX): Assessing Valuation Following Phase 3 Trial Miss and Legal Scrutiny - Yahoo Finance
MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces Securities Fraud Investigation due to Drug Trial Results – Contact BFA Law if You Lost Money - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
MLTX Investor ALERT: Block & Leviton Investigating MoonLake Immunotherapeutics For Securities Fraud; Investors Should Contact The Firm To Potentially Recover Losses - ACCESS Newswire
Why MoonLake Immunotherapeutics (MLTX) Is Down 86.8% After Sonelokimab Phase 3 Trial Misses Key Goal - simplywall.st
MLTX Investor News: If You Have Suffered Losses in MoonLake Immunotherapeutics (NASDAQ: MLTX), ... - Bluefield Daily Telegraph
MarketsMedicine Hat News - FinancialContent
MoonLake Immunotherapeutics down 88% at $7.67 after Phase 3 HS data - MSN
MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors Urged to Contact BFA Law Regarding Securities Fraud Investigation Claims - Newsfile
Equities Analysts Set Expectations for MLTX Q1 Earnings - Defense World
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):